The effect of Naproxen in recovery and reducing mortality in patients with COVID-19

Evaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200410047009N1

Enrollment

101

Registered

2020-04-26

Start date

2020-04-13

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19 disease. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: A group of COVID-19 patients who will receive 500 mg Naproxen tablets 3 times a day for 10 days orally, in addition to the standard treatment provided in the latest

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients whose SARS-CoV-2 infection has been confirmed using PCR Age over 18 years The conscious consent form must be completed and signed by the patient or his companion The patient should participate in the research voluntarily

Exclusion criteria

Exclusion criteria: High creatinine and kidney problems In gastrointestinal ulcers Other conditions of contraindications to the use of Naproxen

Design outcomes

Primary

Measure	Time frame
Recovery in COVID-19 patients. Timepoint: At the beginning (day zero) and the end of the treatment period (day 10). Method of measurement: Examination of clinical signs.;Mortality rate in COVID-19 patients. Timepoint: At the end of treatment period. Method of measurement: The percentage of mortality rate in the study population.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Esghaei

Iran University of Medical Sciences

esghaei.m@iums.ac.ir+98 21 8670 3014

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026